At present, RAD51 inhibitor CYT-0851 has been tested in phase I/II clinical trials, showing selective cytotoxic activity against chronic lymphoblastic leukemia mouse model and human cancer cells, and has the potential to treat B-cell hematological malignant tumors and advanced solid tumors when used alone or in combination with chemotherapy. The gene discussed is RAD51; the disease is cancer.